SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the second quarter ended June 30, 2008.
"The first half of 2008 has been a remarkably productive time at Anadys," said Steve Worland, Ph.D., President and CEO. "Through the focused efforts of our employees, we have initiated dosing in three clinical programs in six months. For hepatitis C, we commenced dosing in our Phase I clinical trial of ANA598 during the second quarter, and are happy to announce today that we have now commenced dosing in our Phase I clinical trial of ANA773 for HCV. We also continue to enroll patients in our ongoing clinical trial of ANA773 for oncology. We are proud of our progress to date and look forward to achieving additional clinical milestones in the coming months."
As of June 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $42.1 million.
During the second quarter of 2008 the Company had no revenue, compared to $1.3 million for the same quarter of 2007. The revenue in the second quarter of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration.
Research and development expenses were $5.5 million for the second
quarter of 2008, compared to $7.0 million for the second quarter of 2007.
The $1.5 million decrease primarily resulted from cost savings derived from
Anadys' completed strategic restructuring and associated termination of
prior development programs. The
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved